Yabao Pharmaceutical Group Co (SHSE:600351) Piotroski F-Score: 7 (As of Jul. 18, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600351 Yabao Pharmaceutical Group Co Ltd SHSE:600351
70 GF Score
Price ¥6.56
GF Value ¥5.53
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Yabao Pharmaceutical Group Co Piotroski F-Score?

Yabao Pharmaceutical Group Co SHSE:600351 -3.53% 70 Piotroski F-Score is 7 as of Jul. 18, 2026, which is at its 10-year median of 7.00. GuruFocus rates SHSE:600351 with a GF Score™ of 70/100 and a GF Value™ of ¥5.53 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 980 Drug Manufacturers companies, Yabao Pharmaceutical Group Co ranks better than 91.73% on this metric.

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Yabao Pharmaceutical Group Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Yabao Pharmaceutical Group Co's Piotroski F-Score or its related term are showing as below:

SHSE:600351' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 7   Max: 9
Current: 7

During the past 13 years, the highest Piotroski F-Score of Yabao Pharmaceutical Group Co was 9. The lowest was 3. And the median was 7.

Yabao Pharmaceutical Group Co  (SHSE:600351) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Yabao Pharmaceutical Group Co Piotroski F-Score Related Terms


Yabao Pharmaceutical Group Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Yabao Pharmaceutical Group Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Yabao Pharmaceutical Group Co Piotroski F-Score Chart

Yabao Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 6.00 8.00 7.00 7.00

Yabao Pharmaceutical Group Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 6.00 6.00 7.00 7.00

SHSE:600351 vs ZTS, UTHR: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Yabao Pharmaceutical Group Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Yabao Pharmaceutical Group Co Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Yabao Pharmaceutical Group Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Yabao Pharmaceutical Group Co's Piotroski F-Score falls into.


SHSE:600351
70GF Score
Yabao Pharmaceutical Group Co Ltd SHSE:600351
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 67.128 + 40.697 + 104.919 + 106.662 = ¥319 Mil.
Cash Flow from Operations was 182.9 + 129.363 + 117.104 + 186.435 = ¥616 Mil.
Revenue was 524.875 + 569.304 + 531.351 + 572.022 = ¥2,198 Mil.
Gross Profit was 273.546 + 292.01 + 285.442 + 304.569 = ¥1,156 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(3569.135 + 3453.586 + 3342.721 + 3286.247 + 3278.717) / 5 = ¥3386.0812 Mil.
Total Assets at the begining of this year (Mar25) was ¥3,569 Mil.
Long-Term Debt & Capital Lease Obligation was ¥36 Mil.
Total Current Assets was ¥1,604 Mil.
Total Current Liabilities was ¥410 Mil.
Net Income was 67.51 + 55.159 + 7.755 + 107.269 = ¥238 Mil.

Revenue was 672.473 + 677.823 + 564.528 + 614.533 = ¥2,529 Mil.
Gross Profit was 348.834 + 314.173 + 290.303 + 325.277 = ¥1,279 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(3797.111 + 3753.941 + 3693.235 + 3543.943 + 3569.135) / 5 = ¥3671.473 Mil.
Total Assets at the begining of last year (Mar24) was ¥3,797 Mil.
Long-Term Debt & Capital Lease Obligation was ¥2 Mil.
Total Current Assets was ¥1,614 Mil.
Total Current Liabilities was ¥559 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Yabao Pharmaceutical Group Co's current Net Income (TTM) was 319. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Yabao Pharmaceutical Group Co's current Cash Flow from Operations (TTM) was 616. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=319.406/3569.135
=0.08949115

ROA (Last Year)=Net Income/Total Assets (Mar24)
=237.693/3797.111
=0.06259838

Yabao Pharmaceutical Group Co's return on assets of this year was 0.08949115. Yabao Pharmaceutical Group Co's return on assets of last year was 0.06259838. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Yabao Pharmaceutical Group Co's current Net Income (TTM) was 319. Yabao Pharmaceutical Group Co's current Cash Flow from Operations (TTM) was 616. ==> 616 > 319 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=36.18/3386.0812
=0.01068492

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=1.88/3671.473
=0.00051206

Yabao Pharmaceutical Group Co's gearing of this year was 0.01068492. Yabao Pharmaceutical Group Co's gearing of last year was 0.00051206. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=1604.431/409.771
=3.91543325

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=1613.88/558.893
=2.88763681

Yabao Pharmaceutical Group Co's current ratio of this year was 3.91543325. Yabao Pharmaceutical Group Co's current ratio of last year was 2.88763681. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Yabao Pharmaceutical Group Co's number of shares in issue this year was 0. Yabao Pharmaceutical Group Co's number of shares in issue last year was 0. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1155.567/2197.552
=0.52584285

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1278.587/2529.357
=0.50549883

Yabao Pharmaceutical Group Co's gross margin of this year was 0.52584285. Yabao Pharmaceutical Group Co's gross margin of last year was 0.50549883. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=2197.552/3569.135
=0.61570997

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=2529.357/3797.111
=0.66612669

Yabao Pharmaceutical Group Co's asset turnover of this year was 0.61570997. Yabao Pharmaceutical Group Co's asset turnover of last year was 0.66612669. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+0+1+1+1+0
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Yabao Pharmaceutical Group Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 7 mean?
Yabao Pharmaceutical Group Co (SHSE:600351) has a Piotroski F-Score of 7 as of Jul. 18, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Yabao Pharmaceutical Group Co and its competitors. This is near median its historical median of 7.00. Over the past decade, Yabao Pharmaceutical Group Co's Piotroski F-Score has ranged from 3.00 to 9.00. According to the industry distribution chart, Yabao Pharmaceutical Group Co ranks #81 out of 980 companies in the Drug Manufacturers industry, placing it in the top 8.3%.
Is Yabao Pharmaceutical Group Co's Piotroski F-Score too high?
Yabao Pharmaceutical Group Co's current Piotroski F-Score of 7 is near median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 9.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Yabao Pharmaceutical Group Co's value of 7 is 40% above this industry median. Based on the distribution chart, Yabao Pharmaceutical Group Co ranks #81 out of 980 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Yabao Pharmaceutical Group Co has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Yabao Pharmaceutical Group Co's Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Yabao Pharmaceutical Group Co ranks #81 out of 980 companies for Piotroski F-Score. This places Yabao Pharmaceutical Group Co in the top 8% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Yabao Pharmaceutical Group Co's value of 7 is 40% above this benchmark. Historically, Yabao Pharmaceutical Group Co's own Piotroski F-Score has ranged from 3.00 to 9.00 over the past decade. While the company's 10-year median is 7.00 vs. the industry median of 5.00, Yabao Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 980 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Yabao Pharmaceutical Group Co's current Piotroski F-Score of 7 is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Yabao Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Yabao Pharmaceutical Group Co's current Piotroski F-Score is 7, which is near median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yabao Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Yabao Pharmaceutical Group Co (SHSE:600351) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥5.53, compared to a current price of ¥6.56 — trading 18.6% above its estimated fair value. The current Piotroski F-Score is 7, which is near median its 10-year median of 7.00 and 40% above the Drug Manufacturers industry median of 5.00. Yabao Pharmaceutical Group Co's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Yabao Pharmaceutical Group Co (SHSE:600351), the current Piotroski F-Score is 7 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Yabao Pharmaceutical Group Co (SHSE:600351) Overvalued in 2026?

Based on GuruFocus' analysis, Yabao Pharmaceutical Group Co stock appears to be overvalued. The current stock price of ¥6.56 is trading 18.6% above its estimated GF Value™ of ¥5.53. GuruFocus considers Yabao Pharmaceutical Group Co to be Modestly Overvalued.

Key valuation signals for SHSE:600351:

  • Piotroski F-Score: 7 (near median its 10-year median of 7.00)
  • GF Value™: ¥5.53 vs. price of ¥6.56 (18.6% above fair value)
  • GF Score™: 70/100 with 3 warning signs
  • Industry Position: 40% above the Drug Manufacturers median (#81 of 980)

No single metric tells the full story. See the SHSE:600351 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Yabao Pharmaceutical Group Co Business Description

Address No.43 Fumin Road, Ruicheng, Shanxi Province, Yuncheng, CHN, 044602
Yabao Pharmaceutical Group Co Ltd is engaged in the manufacture and operation of western and Chinese medicines, APIs, health care products, packing materials for medicine, and also engages in the planting and processing of medicinal herbs.
70GF Score

Get the complete analysis for SHSE:600351

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥6.56
Price
¥5.53
GF Value